



**FOR IMMEDIATE RELEASE**

## **Compugen to Present at Upcoming Immuno-Oncology and Rheumatology Conferences**

Tel Aviv, September 9, 2015 – Compugen Ltd. ([NASDAQ: CGEN](#)), a leading predictive drug discovery company, today announced that aspects of its immuno-oncology programs and its lead autoimmune program will be presented at four upcoming scientific conferences.

In poster presentations at three upcoming oncology conferences, Compugen's scientists will present the Company's unique predictive discovery approach for novel drug targets with an emphasis on selected novel immune checkpoint programs which are now being advanced by the Company in the field of cancer immunotherapy.

Arthur Machlenkin, Ph.D., Head of Immuno-Oncology Research at Compugen, will present at the [CRI-CIMT-EATI-AACR - The Inaugural International Cancer Immunotherapy Conference: Translating Science into Survival](#), to be held between September 16-19, 2015, in New York.

Ofer Levy, Ph.D., Principal Scientist at Compugen, will present at the [7th International Conference on Tumor Microenvironment](#), to be held between October 11-15, 2015, in Tel Aviv, Israel.

Galit Rotman, Ph.D., Chief Scientist, Therapeutics at Compugen will present at the [Society for Immunotherapy of Cancer's \(SITC's\) 30th Anniversary Annual Meeting & Associated Programs](#), to be held between November 4-8, 2015, in National Harbor, MD.

The Company's lead program for autoimmune diseases, CGEN-15001, a therapeutic fusion protein based on a Compugen-discovered immune checkpoint protein candidate, will be the subject of an oral presentation by Iris Hecht, Ph.D., Principal Scientist at Compugen, at the [American College of Rheumatology Annual Meeting](#) to take place between November 6-11, 2015, in San Francisco. Dr. Hecht's talk, on Sunday, November 8, titled "CGEN-15001, a Novel B7-like Protein, Controls Inflammation in a Translational Rheumatoid Arthritis (RA) Assay and Induces Treg Driven Long-Term Remission in an Autoimmune Disease Model," will be given as part of the Cytokines, Mediators, Cell-cell Adhesion, Cell Trafficking and Angiogenesis session and will include recent data for CGEN-15001 obtained using immune cells of rheumatoid arthritis patients.

## **About Compugen**

Compugen is a leading drug discovery company utilizing its broadly applicable predictive discovery infrastructure to identify novel drug targets and develop first-in-class biologics. The Company's current pipeline focus is on immune checkpoint target candidates discovered by the Company, potentially providing the basis for a next wave of therapeutics for cancer immunotherapy. Compugen's business model is based on selectively entering into collaborations for its novel targets and drug product candidates at various stages of research and development under revenue-sharing agreements. The Company is headquartered in Tel Aviv, Israel, with R&D facilities in Tel Aviv and South San Francisco. At the US facilities, monoclonal antibody therapeutic candidates are discovered and developed against the Company's novel target candidates. For additional information, please visit Compugen's corporate website at [www.cgen.com](http://www.cgen.com).

## **Forward Looking Statement**

This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by the use of terminology such as "will," "may," "expects," "anticipates," "believes," and "intends," and describe opinions about future events. These forward-looking statements involve known and unknown risks and uncertainties that may cause the actual results, performance or achievements of Compugen to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Some of these risks include: that Compugen's business model is substantially dependent on entering into collaboration agreements with third parties and may not be successful in generating revenues, and that the development and commercialization of therapeutic products includes many inherent risks, including failure to progress to clinic or, if progressed, failure to receive regulatory approval. These and other factors are more fully discussed in the "Risk Factors" section of Compugen's most recent Annual Report on Form 20-F as filed with the Securities and Exchange Commission as well as other documents that may be subsequently filed by Compugen from time to time with the Securities and Exchange Commission. In addition, any forward-looking statements represent Compugen's views only as of the date of this release and should not be relied upon as representing its views as of any subsequent date. Compugen does not assume any obligation to update any forward-looking statements unless required by law.

### **Company contact:**

Tsipi Haitovsky  
Global Media Liaison  
Compugen Ltd.  
Email: [tsipih@cgen.com](mailto:tsipih@cgen.com)  
Tel: +972-52-598-9892